Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Catch up with the monthly messages from the Director of the NIHR HTA Programme

OCTRU

Professor Hywel Williams the Director of the NIHR HTA Programme writes a monthly Director’s Message. This month’s message includes Hywel’s tips on how to improve your research application by getting a review from outside of your team, and Hywel’s appreciation of NIHR.

Visit the below You Tube link to see this month's message and previous messages.

https://www.youtube.com/watch?v=6tL5EqPoPGI&index=1&list=PLIa1oelW_zJ-ah4F-3P_hL8G_mdIzSD4q 

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Fancy joining our team?

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.